When combined with low doses of interleukin-2 (IL-2) as co-treatment, BrHPP even demonstrated strong potential in specific activation of Vγ9Vδ2 T cells in clinical trials for the treatment of hematological malignancies and solid tumors [105,106]. This evidence concerns the gene IL2 and hematologic disorder.